RNASET2 and gastric adenocarcinoma: For example, in ovarian cancer, gastric adenocarcinoma and melanoma, downregulation of RNASET2 significantly enhanced the malignant phenotype of the tumor and correlated with a worsening of the patient’s clinical outcome [11–13].